Facebook Instagram Linkedin Youtube
Home Search

Elicera - search results

If you're not happy with the results, please do another search
Elicera Material Transfers Agreement USA

Elicera collaborates with US cancer centre to evaluate iTANK

Full speed ahead for Elicera in 2024

Full speed ahead for Elicera in 2024

Elicera klinisk CAR T-studie

Elicera gets green light for CAR T clinical study

FDA CAR T investigation does not affect Elicera

FDA CAR T investigation does not affect Elicera

Elicera_Legend_Novartis agreement

CAR T deal puts spotlight on Elicera’s technology

Elicera's CEO: " iTANK has great potential in treating solid tumours"

Elicera’s CEO: ” iTANK has great potential in treating solid tumours”

All sessions from BioStock Life Science Fall Summit 2023

Panel at BioStock Life Science Fall Summit 2023

Video from day 2 of BioStock Life Science Fall Summit 2023

LSX Nordic Congress Interviews

Interviews from LSX Nordic Congress 

Elicera_NatureCommunications

Elicera’s potential in cancer therapy published in Nature Communications

Elicera_EU_patent

Elicera Therapeutics receives important EU patent

Elicera uppdaterar i samband med Cancer Immunotherapy Month

Elicera gives an update in Cancer Immunotherapy Month

biostock life science summit 2023

The BioStock Life Science Spring Summit 2023 goes live today

Elicera Q1 2023

Well-financed Elicera prepared for clinic and business development

Janssen CAR T deal supports Elicera’s vision

Janssen CAR T deal supports Elicera’s vision

Elicera CAR T potential

Elicera on CAR T-cells’ potential beyond blood cancer

Elicera Q4 2022

Advancements for Elicera in 2022 open for intensive clinical year

AstraZeneca boasts strong 2022

Strong AstraZeneca sees continued growth

Elicera comments on AstraZeneca acquisition of Neogene Therapeutics

Elicera on AstraZeneca’s acquisition of Neogene Therapeutics

CAR T therapy revolution cancer

The CAR T revolution in the fight against cancer

Elicera fas I signaler

Elicera on the positive clinical effect in cancer trial

Elicera iTANK partnering intensifies

Elicera’s CEO: “iTANK partnering is intensifying”

Elicera Therapeutics enters first international collaboration involving iTANK

NLSDays

NLSDays: Interviews with 10 interesting companies

Jamal El Mosleh, CEO Elicera Therapeutics

BioStock Investor Meeting: Interview with Elicera Therapeutics

Jamal El-Mosleh, vd Elicera

BioStock Investor Meeting: Elicera Therapeutics presents

Elicera strong financial

Elicera Therapeutics strengthens financial standing in Q2

BioStock Investor Meeting, September 14

Funding

Elicera receives funding for clinical trials with ELC-301

Elicera proof of concept

Elicera continues to deliver proof-of-concept data

ELICERA's CSO and Co-founder MAGNUS ESSAND

BioStock Studio: Elicera’s immuno-oncology platform iTANK reaches high-impact journal

Elicera well-positioned to thrive in 2022

Elicera well-positioned to thrive in 2022

Elicera Therapeutics partners with Baylor College of Medicine

Elicera Therapeutics partners with Baylor College of Medicine

Elicera Therapeutics keeps strong momentum after IPO

Elicera Therapeutics keeps strong momentum after IPO

Elicera Therapeutics enters agreement with BioNTech

Elicera Therapeutics enters agreement with BioNTech 

Elicera reaches Proof of Concept

Elicera Therapeutics’ iTANK-platform reaches proof-of-concept

Elicera Therapeutics comes out of the gate running in Q2

Successful new share issue provides tailwinds for Elicera Therapeutics

Elicera receives ATMP classification from EMA

Elicera Therapeutics

Status report Elicera Therapeutics – Pushing the boundaries of immuno-oncology

BioStock Live with Elicera Therapeutics

Elicera_BMS_iTANK

BMS CAR T-cell approval: Elicera sees an opening

Elicera Therapeutics takes immuno-oncology to the next level

© BioStock 2024